Creso Pharma


GW Pharmaceuticals plc

GWPH


Canadian symbol: GWPH
US symbol: GWPH

Currency in USD

Valuation Measures

Market Cap (intraday) 54.58B
Enterprise Value 34.24B
Trailing P/E N/A
Forward P/E 1357.69
PEG Ratio (5 yr expected) 1-0.46
Price/Sales (ttm)9.39
Price/Book (mrq)6.38
Enterprise Value/Revenue 38.70
Enterprise Value/EBITDA 6-112.36

Trading Information

Stock Price History

Beta (5Y Monthly) 2.15
52-Week Change 331.63%
S&P500 52-Week Change 317.60%
52 Week High 3151.11
52 Week Low 367.98
50-Day Moving Average 3125.63
200-Day Moving Average 3115.04

Share Statistics

Avg Vol (3 month) 3412.45k
Avg Vol (10 day) 3351.38k
Shares Outstanding 531.18M
Float 30.5M
% Held by Insiders 10.64%
% Held by Institutions 184.41%
Shares Short (Dec. 30, 2020) 42.96M
Short Ratio (Dec. 30, 2020) 49.31
Short % of Float (Dec. 30, 2020) 4N/A
Short % of Shares Outstanding (Dec. 30, 2020) 49.49%
Shares Short (prior month Nov. 29, 2020) 43.54M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Sep. 29, 2020

Profitability

Profit Margin -11.05%
Operating Margin (ttm)-10.05%

Management Effectiveness

Return on Assets (ttm)-3.49%
Return on Equity (ttm)-7.42%

Income Statement

Revenue (ttm)488.06M
Revenue Per Share (ttm)15.64
Quarterly Revenue Growth (yoy)50.70%
Gross Profit (ttm)284.13M
EBITDA -37.77M
Net Income Avi to Common (ttm)-53.93M
Diluted EPS (ttm)-1.73
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)480.33M
Total Cash Per Share (mrq)15.4
Total Debt (mrq)39.95M
Total Debt/Equity (mrq)5.44
Current Ratio (mrq)5.13
Book Value Per Share (mrq)23.55

Cash Flow Statement

Operating Cash Flow (ttm)-49.26M
Levered Free Cash Flow (ttm)-56.49M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
GWPH
GW Pharmaceuticals plc
2 days ago
GWPH
GW Pharmaceuticals plc
5 days ago
GWPH
GW Pharmaceuticals plc
2 weeks ago
GWPH
GW Pharmaceuticals plc
2 weeks ago
GWPH
GW Pharmaceuticals plc
2 weeks ago
GWPH
GW Pharmaceuticals plc
2 weeks ago
GWPH
GW Pharmaceuticals plc
2 weeks ago
GWPH
GW Pharmaceuticals plc
2 weeks ago
GWPH
GW Pharmaceuticals plc
2 weeks ago
GWPH
GW Pharmaceuticals plc
3 weeks ago
GWPH
GW Pharmaceuticals plc
3 weeks ago
GWPH
GW Pharmaceuticals plc
3 weeks ago
GWPH
GW Pharmaceuticals plc
3 weeks ago
GWPH
GW Pharmaceuticals plc
3 weeks ago
GWPH
GW Pharmaceuticals plc
1 month ago
GWPH
GW Pharmaceuticals plc
1 month ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
6 months ago
GWPH
GW Pharmaceuticals plc
6 months ago
GWPH
GW Pharmaceuticals plc
6 months ago
GWPH
GW Pharmaceuticals plc
6 months ago
GWPH
GW Pharmaceuticals plc
6 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
8 months ago
GWPH
GW Pharmaceuticals plc
8 months ago
GWPH
GW Pharmaceuticals plc
8 months ago
GWPH
GW Pharmaceuticals plc
8 months ago
GWPH
GW Pharmaceuticals plc
8 months ago
GWPH
GW Pharmaceuticals plc
8 months ago
GWPH
GW Pharmaceuticals plc
8 months ago
GWPH
GW Pharmaceuticals plc
8 months ago
GWPH
GW Pharmaceuticals plc
8 months ago
GWPH
GW Pharmaceuticals plc
8 months ago
GWPH
GW Pharmaceuticals plc
8 months ago
GWPH
GW Pharmaceuticals plc
8 months ago
GWPH
GW Pharmaceuticals plc
8 months ago
GWPH
GW Pharmaceuticals plc
8 months ago
GWPH
GW Pharmaceuticals plc
8 months ago
GWPH
GW Pharmaceuticals plc
8 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
12 months ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago

Currency in USD
Earnings EstimateCurrent Qtr. (Dec 2020)Next Qtr. (Mar 2021)Current Year (2020)Next Year (2021)
No. of Analysts4224
Avg. Estimate-0.82-0.36-1.850.42
Low Estimate-1.22-0.6-2.15-1.17
High Estimate-0.62-0.13-1.551.76
Year Ago EPS-0.84-0.24-0.24-1.85
Revenue EstimateCurrent Qtr. (Dec 2020)Next Qtr. (Mar 2021)Current Year (2020)Next Year (2021)
No. of Analysts1471515
Avg. Estimate142.57M156.62M522.32M737.83M
Low Estimate131.31M154.7M510.3M663M
High Estimate148.54M158.76M533.81M995.43M
Year Ago Sales109.08M120.63M311.33M522.32M
Sales Growth (year/est)30.70%29.80%67.80%41.30%
Earnings History2019-12-302020-03-302020-06-292020-09-29
EPS Est.-0.52-0.85-0.63-0.83
EPS Actual-0.84-0.24-0.24-0.36
Difference-0.320.610.390.47
Surprise %-61.50%71.80%61.90%56.60%
EPS TrendCurrent Qtr. (Dec 2020)Next Qtr. (Mar 2021)Current Year (2020)Next Year (2021)
Current Estimate-0.82-0.36-1.850.42
7 Days Ago-0.82-0.36-1.850.42
30 Days Ago-0.82-0.36-1.850.42
60 Days Ago-0.8-0.13-1.761.2
90 Days Ago-0.91-0.18-2.281.93
EPS RevisionsCurrent Qtr. (Dec 2020)Next Qtr. (Mar 2021)Current Year (2020)Next Year (2021)
Up Last 7 Days1N/A1N/A
Up Last 30 Days5153
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/A1
Growth EstimatesGWPHIndustrySector(s)S&P 500
Current Qtr.2.40%N/AN/AN/A
Next Qtr.-50.00%N/AN/AN/A
Current Year-670.80%N/AN/AN/A
Next Year122.70%N/AN/AN/A
Next 5 Years (per annum)159.40%N/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in USD
Breakdown
0.64%% of Shares Held by All Insider
84.41%% of Shares Held by Institutions
84.95%% of Float Held by Institutions
343Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Capital Research Global Investors3,732,712Sep. 29, 202012.07%363,379,513
Capital World Investors2,754,644Sep. 29, 20208.91%268,164,593
Franklin Resources, Inc.2,232,259Sep. 29, 20207.22%217,310,413
Janus Henderson Group PLC2,041,289Sep. 29, 20206.60%198,719,484
Canada Pension Plan Investment Board1,500,000Sep. 29, 20204.85%146,025,000
Federated Hermes, Inc.861,744Sep. 29, 20202.79%83,890,778
Morgan Stanley830,565Sep. 29, 20202.69%80,855,502
Victory Capital Management Inc.573,752Sep. 29, 20201.86%55,854,757
Bellevue Group AG562,943Sep. 29, 20201.82%54,802,501
Point72 Asset Management, L.P.542,164Sep. 29, 20201.75%52,779,665

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
Fundamental Investors Inc2,000,000Dec. 30, 20206.47%230,820,000
Smallcap World Fund1,799,395Sep. 29, 20205.82%175,171,103
New Economy Fund (The)1,289,410Dec. 30, 20204.17%148,810,808
Europacific Growth Fund678,443Dec. 30, 20202.19%78,299,106
Janus Henderson Triton Fund629,433Sep. 29, 20202.04%61,275,302
Federated Hermes Kaufmann Fund505,142Oct. 30, 20201.63%45,467,831
American Funds Insurance Ser-Global Small Capitalization Fund473,768Dec. 30, 20201.53%54,677,564
Franklin Strategic Series-Franklin Biotechnology Discove437,300Oct. 30, 20201.41%39,361,373
Janus Henderson Global Life Sciences Fund420,092Sep. 29, 20201.36%40,895,956
ETF Managers Tr-EFTMG Alternative Harvest ETF375,344Sep. 29, 20201.21%36,539,738
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by GW Pharmaceuticals plc


GW Pharmaceuticals Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones

GW Pharmaceuticals Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones

- Total preliminary net product sales of approximately $148 million for the fourth quarter and approximately $526 million for the full year -- Total Epidiolex® preliminary net product sales of approximately $144 million for the fourth quarter and approximately $510 million for the full year –- Pivotal US clinical program for nabiximols in... Read More...
CORRECTING and REPLACING - GW Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

CORRECTING and REPLACING – GW Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

LONDON and CARLSBAD, Calif., Jan. 05, 2021 -- In a release issued earlier today by GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group) under the same headline, please note the time of the conference and breakout session have changed. The conference will be held Tuesday, January 12, 2021 at 10:00 am ET (7:00 am PT). The bre... Read More...
JAMA Neurology Publishes Phase 3 Study of EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated with Tuberous Sclerosis Complex

JAMA Neurology Publishes Phase 3 Study of EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated with Tuberous Sclerosis Complex

CARLSBAD, Calif., Dec. 21, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that JAMA Neurology has published results of the company’s posi... Read More...
GW Pharmaceuticals to Present at the 2020 Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference

GW Pharmaceuticals to Present at the 2020 Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference

LONDON and CARLSBAD, Calif., Dec. 07, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Co... Read More...
Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

- Meeting Highlights Include New Long-Term Data in Tuberous Sclerosis Complex -CARLSBAD, Calif., Dec. 01, 2020 -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that a variety... Read More...
GW Pharmaceuticals to Present at the Evercore ISI 2020 Healthcare Conference

GW Pharmaceuticals to Present at the Evercore ISI 2020 Healthcare Conference

LONDON and CARLSBAD, Calif., Nov. 30, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020 a... Read More...
Greenwich Biosciences to Present Analysis of Three Clinical Studies of Nabiximols for People with Multiple Sclerosis Related Spasticity at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly

Greenwich Biosciences to Present Analysis of Three Clinical Studies of Nabiximols for People with Multiple Sclerosis Related Spasticity at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly

- Results from analysis of three Phase 3 clinical studies showed statistically significant improvement in spasticity in people with multiple sclerosis- Treatment with nabiximols seen in this analysis was not associated with increased muscle weakness or a notable change in preferred walking speed CARLSBAD, Calif., Nov. 13, 2020 -- Greenwic... Read More...
GW Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference

GW Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference

LONDON and CARLSBAD, Calif., Nov. 09, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18, 202... Read More...
GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress

GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress

- Total revenue increased 51 percent to $137.1 million – - Epidiolex for seizures associated with TSC launched in the U.S. -- Nabiximols Phase 3 program in MS spasticity now recruiting -- Conference call today at 8:30 a.m. EST -LONDON and CARLSBAD, Calif., Nov. 03, 2020 -- GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the scien... Read More...
GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity

GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity

CARLSBAD, Calif., Nov. 03, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today announced that the Company has initiated the first U.S. Phase 3 clinical tr... Read More...
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30th, 2020 and Host Conference Call on November 3rd, 2020

GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30th, 2020 and Host Conference Call on November 3rd, 2020

LONDON and CARLSBAD, Calif., Oct. 22, 2020 -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on November 3rd, 2020 its financial results and operational progr... Read More...
Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy Community

Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy Community

-- Technology provides a new way for the community to communicate and connect ---- Launching in collaboration with patient advocacy organizations, this web-based, image-recognition technology bridges music and art to provide a voice for those who struggle to express themselves -- CARLSBAD, Calif., Oct. 21, 2020 -- Greenwich Biosciences, I... Read More...
GW Pharmaceuticals receives Australian Therapeutic Goods Administration (TGA) approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

GW Pharmaceuticals receives Australian Therapeutic Goods Administration (TGA) approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

LONDON, Sept. 23, 2020 -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the Australian Therapeutic Goods Administration (TGA) has approved EPIDYOLEX® (cannabidiol) for the treatment of s... Read More...
Greenwich Biosciences to Share Results of Cannabis Use Survey Conducted with the North American Research Committee on Multiple Sclerosis (NARCOMS) at Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020

Greenwich Biosciences to Share Results of Cannabis Use Survey Conducted with the North American Research Committee on Multiple Sclerosis (NARCOMS) at Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020

CARLSBAD, Calif., Sept. 10, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, will present results of a survey conducted in partnership with the North America... Read More...
Greenwich Biosciences to Present Data on Safety and Efficacy of Nabiximols in Persons with Multiple Sclerosis-Associated Spasticity at the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020

Greenwich Biosciences to Present Data on Safety and Efficacy of Nabiximols in Persons with Multiple Sclerosis-Associated Spasticity at the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020

- Results from post-hoc analysis of phase 3 clinical study show nabiximols was well-tolerated and provided continued reductions in spasticity for individuals who remained on therapy- Analysis of two placebo-controlled randomized trials shows nabiximols had no notable negative effects on cognition, depression, or suicidality CARLSBAD, Cali... Read More...
GW Pharmaceuticals Announces the Appointment of David Gryska to its Board of Directors

GW Pharmaceuticals Announces the Appointment of David Gryska to its Board of Directors

LONDON, Sept. 10, 2020 -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines today announced the appointment of David Gryska to the Board of Directors. Mr. Gryska will also serve as a member of the Audit Committee. Mr. Gryska brings valuable glob... Read More...
GW Pharmaceuticals plc Reports Second Quarter 2020 Financial Results and Operational Progress

GW Pharmaceuticals plc Reports Second Quarter 2020 Financial Results and Operational Progress

- Total revenue increased 68 percent to $121.3 million - - Epidiolex approved in the U.S. for seizures associated with TSC, launch expected this month -- Conference call today at 4:30 p.m. EDT –LONDON and CARLSBAD, Calif., Aug. 06, 2020 -- GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercializa... Read More...
FDA Approves EPIDIOLEX® (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex

FDA Approves EPIDIOLEX® (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex

– Age-range for all EPIDIOLEX indications expanded to include patients one year of age and older –– Third indication approved for EPIDIOLEX, the only FDA-approved Cannabidiol (CBD) medicine –                    CARLSBAD, Calif., Aug. 03, 2020 -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and comme... Read More...
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Second Quarter Ending June 30th, 2020 and Host Conference Call on August 6th, 2020

GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Second Quarter Ending June 30th, 2020 and Host Conference Call on August 6th, 2020

LONDON and CARLSBAD, Calif., July 23, 2020 -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on August 6th, 2020 its financial results and operational progres... Read More...
GW Pharmaceuticals Presents Nabiximols U.S. Development and Commercial Strategy

GW Pharmaceuticals Presents Nabiximols U.S. Development and Commercial Strategy

 - Potential accelerated pathway to NDA submission - - Clinical program of five Phase 3 trials provides multiple options for NDA submission, as early as 2021 -- Webcast featuring a range of guest speakers to be held today from 10:00am-12:00pm EDT -CARLSBAD, Calif., June 30, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or ... Read More...
GW Pharmaceuticals announces that EPIDYOLEX® (cannabidiol) has been reclassified by the UK Home Office as a Schedule 5 drug

GW Pharmaceuticals announces that EPIDYOLEX® (cannabidiol) has been reclassified by the UK Home Office as a Schedule 5 drug

GW’s cannabis-based medicine rescheduled following approval by the European Medicines Agency (EMA) and an independent assessment by the Advisory Council on the Misuse of Drugs (ACMD)Burden on patients, their families and healthcare professionals eased due to the reduction in controlled drug requirements   LONDON, June 24, 2020 -- GW Pharm... Read More...
GW Pharmaceuticals to Host Virtual Investor Event on Its Nabiximols U.S. Development Program and Market Opportunity

GW Pharmaceuticals to Host Virtual Investor Event on Its Nabiximols U.S. Development Program and Market Opportunity

LONDON and CARLSBAD, Calif., June 04, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW or the Company), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will host a virtual event for investors to provide a review of the U.S. development program and ma... Read More...
GW Pharmaceuticals plc Reports First Quarter 2020 Financial Results and Operational Progress

GW Pharmaceuticals plc Reports First Quarter 2020 Financial Results and Operational Progress

- Total revenue of $120.6 million - - Total Epidiolex® net product sales of $116.1 million - - Conference call today at 4:30 p.m. EDT –LONDON and CARLSBAD, Calif., May 11, 2020 -- GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announces ... Read More...
GW Pharmaceuticals to Present at the Bank of America Healthcare Conference 2020

GW Pharmaceuticals to Present at the Bank of America Healthcare Conference 2020

LONDON and CARLSBAD, Calif., May 01, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present a business update at the Bank of America He... Read More...
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the First Quarter Ending March 31st, 2020 and Host Conference Call on May 11th, 2020

GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the First Quarter Ending March 31st, 2020 and Host Conference Call on May 11th, 2020

CARLSBAD, Calif., April 21, 2020 -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on May 11th, 2020 its financial results for the first quarter ending March ... Read More...
GW Pharmaceuticals plc and Its U.S. Subsidiary Greenwich Biosciences, Inc. Announce That EPIDIOLEX® (cannabidiol) Oral Solution Has Been Descheduled And Is No Longer A Controlled Substance

GW Pharmaceuticals plc and Its U.S. Subsidiary Greenwich Biosciences, Inc. Announce That EPIDIOLEX® (cannabidiol) Oral Solution Has Been Descheduled And Is No Longer A Controlled Substance

- Descheduling will enable prescribing free of the previous Schedule V requirements -CARLSBAD, Calif., April 06, 2020 -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid platform,... Read More...
GW Pharmaceuticals and Greenwich Biosciences Announce FDA Acceptance of sNDA Filing with Priority Review for EPIDIOLEX® (cannabidiol) in the Treatment of Seizures Associated with Tuberous Sclerosis Complex

GW Pharmaceuticals and Greenwich Biosciences Announce FDA Acceptance of sNDA Filing with Priority Review for EPIDIOLEX® (cannabidiol) in the Treatment of Seizures Associated with Tuberous Sclerosis Complex

CARLSBAD, Calif., March 31, 2020 -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, Inc., today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Prio... Read More...
GW Pharmaceuticals submits Type II Variation Application to the European Medicines Agency (EMA) to expand the use of EPIDYOLEX®, (cannabidiol) oral solution, for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC)

GW Pharmaceuticals submits Type II Variation Application to the European Medicines Agency (EMA) to expand the use of EPIDYOLEX®, (cannabidiol) oral solution, for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC)

LONDON, March 13, 2020 -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and commercialising cannabinoid prescription medicines, today announces the submission of a Type II Variation Application to the European Medicines Agency (EMA) seeking approval of EPIDYOLEX®, (ca... Read More...
JAMA Neurology Publishes Results from Positive Phase 3 Trial of EPIDIOLEX® (cannabidiol) oral solution in Children with Seizures Associated with Dravet Syndrome

JAMA Neurology Publishes Results from Positive Phase 3 Trial of EPIDIOLEX® (cannabidiol) oral solution in Children with Seizures Associated with Dravet Syndrome

CARLSBAD, Calif., March 02, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that JAMA Neurology has published results from the second posi... Read More...
GW Pharmaceuticals regains exclusive commercialisation rights to Sativex® (nabiximols) in the UK from Bayer

GW Pharmaceuticals regains exclusive commercialisation rights to Sativex® (nabiximols) in the UK from Bayer

CAMBRIDGE, United Kingdom and READING, United Kingdom, March 02, 2020 -- GW Pharmaceuticals plc (GW) and Bayer plc, the life science company, today announce that GW will regain exclusive UK commercialisation rights for Sativex® (delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)) from Bayer.Sativex, often known by the USAN name nabi... Read More...
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2019 Financial Results and Operational Progress

GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2019 Financial Results and Operational Progress

- Total revenue of $109.1 million for the fourth quarter and $311.3 million for the full year -- Total Epidiolex® net product sales of $104.5 million for the fourth quarter and $296.4 million for the first full year of sales - - Conference call today at 4:30 p.m. EST - LONDON and CARLSBAD, Calif., Feb. 25, 2020 -- GW Pharmaceuticals plc (... Read More...
GW Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference

GW Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference

LONDON and CARLSBAD, Calif., Feb. 24, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present a business update at the Cowen 40th Annual... Read More...
GW Pharmaceuticals and Greenwich Biosciences Submit Supplemental New Drug Application to U.S. FDA for Epidiolex® (cannabidiol) for the Treatment of Tuberous Sclerosis Complex

GW Pharmaceuticals and Greenwich Biosciences Submit Supplemental New Drug Application to U.S. FDA for Epidiolex® (cannabidiol) for the Treatment of Tuberous Sclerosis Complex

LONDON and CARLSBAD, Calif., Feb. 03, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, Inc., announced today that it has submitted a supplemental New D... Read More...
GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

- Total preliminary net product sales of approximately $108 million for the fourth quarter and approximately $309 million for the full year - - Total Epidiolex® preliminary net product sales of approximately $104 million for the fourth quarter and approximately $296 million for the first full year of sales -LONDON and CARLSBAD, Calif., Ja... Read More...
GW Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

GW Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

LONDON and CARLSBAD, Calif., Jan. 07, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present a business update at the 38th Annual J.P... Read More...
Greenwich Biosciences, a GW Pharmaceuticals Company, Presents New Data for EPIDIOLEX® (cannabidiol) in Patients with Tuberous Sclerosis Complex (TSC) at the American Epilepsy Society Annual Meeting

Greenwich Biosciences, a GW Pharmaceuticals Company, Presents New Data for EPIDIOLEX® (cannabidiol) in Patients with Tuberous Sclerosis Complex (TSC) at the American Epilepsy Society Annual Meeting

CARLSBAD, Calif., Dec. 07, 2019 -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today presented new data from a Phase 3 clinical trial of EPIDIOLEX® (cannabidiol or CBD) oral solution, CV i... Read More...
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

LONDON and CARLSBAD, Calif., Dec. 05, 2019 -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences announced today that a variety of data, including results from completed Phase 3 trials of EPIDIOLE... Read More...
GW Pharmaceuticals to Present at Upcoming Investor Conferences

GW Pharmaceuticals to Present at Upcoming Investor Conferences

CARLSBAD, Calif., Nov. 22, 2019 -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present ... Read More...
GW Pharmaceuticals receives positive NICE recommendation for EPIDYOLEX® (cannabidiol) oral solution for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

GW Pharmaceuticals receives positive NICE recommendation for EPIDYOLEX® (cannabidiol) oral solution for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

GW also welcomes the positive guideline recommendation for Sativex® (nabiximols) for the treatment of spasticity due to multiple sclerosis as part of NICE’s evaluation of cannabis-based medicinal products (CBMPs)Cannabidiol oral solution and nabiximols are the first and only plant-derived cannabis-based medicines to be routinely reimburse... Read More...
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019

GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019

- Epidiolex U.S. year to date net sales of $188.0 million, including Q3 net sales of $86.1 million - - Conference call today at 4:30 p.m. ET -CARLSBAD, Calif., Nov. 05, 2019 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the discovery, development and commercialization of cannabinoid prescripti... Read More...
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30, 2019 and Host Conference Call on November 5, 2019

GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30, 2019 and Host Conference Call on November 5, 2019

CARLSBAD, Calif., Oct. 09, 2019 -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on November 5th, 2019 its financial results for the third quarter ending Sep... Read More...
GW Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2nd, 2019

GW Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2nd, 2019

CARLSBAD, Calif., Sept. 24, 2019 -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, today announced that Scott Giacobello, GW’s Chief Financial Officer and Stephen Schultz... Read More...
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

Cannabidiol oral solution is the first plant-derived cannabis-based medicine to be approved by the European Medicines Agency (EMA)Cannabidiol oral solution contains highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the “high” associated with cannabis LONDON and CARLSBAD, Calif., Sept. 23, 2019 -- GW Pharmaceuticals p... Read More...
GW Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, September 11th, 2019

GW Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, September 11th, 2019

CARLSBAD, Calif., Sept. 04, 2019 -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer will present ... Read More...
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2019

GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2019

- Epidiolex U.S. Q2 net sales of $68.4 million - - Positive CHMP opinion clears way for an expected European approval in October - - Conference call today at 4:30 p.m. EST -CARLSBAD, Calif., Aug. 06, 2019 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development and commercializat... Read More...
GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX™ (cannabidiol oral solution) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX™ (cannabidiol oral solution) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

If approved cannabidiol oral solution will be the first plant-derived cannabis-based medicine to be approved in Europe for the treatment of any form of epilepsyGW’s cannabidiol oral solution contains highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the “high” associated with cannabis LONDON and CARLSBAD, Calif., Jul... Read More...
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending June 30, 2019 and Host Conference Call on August 6, 2019

GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending June 30, 2019 and Host Conference Call on August 6, 2019

LONDON, July 23, 2019 -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on August 6, 2019 its financial results for the quarter ending June 30, 2019. GW will ... Read More...
GW Pharmaceuticals to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th, 2019

GW Pharmaceuticals to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th, 2019

CARLSBAD, Calif., June 04, 2019 -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Stephen Schultz, GW’s Vice President of Investor Relation... Read More...
GW Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019

GW Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019

LONDON, May 09, 2019 -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the Bank... Read More...
Coming Soon.

Delayed data (1h)


Share this page